Ocrelizumab UTI Signal

A Food and Drug Administration adverse-event analysis found ocrelizumab had the strongest reporting link to urinary tract infections among multiple sclerosis drugs. (aan.com) The analysis, presented at the American Academy of Neurology meeting in April 2026, reviewed Food and Drug Administration Adverse Event Reporting System reports from 2003 through 2024. It identified 12,997 urinary tract infection reports and 651 urosepsis reports in people with multiple sclerosis whose disease-modifying therapy was listed as the primary suspect drug. (aan.com) Ocrelizumab showed the highest disproportionality signal for urinary tract infections, while natalizumab, alemtuzumab, and interferon beta-1a showed signals for both urinary tract infections and urosepsis across sex and age subgroups. Nearly 7,000 of the cases involved hospitalization, and more than 500 deaths were reported in the database review. (index.mirasmart.com) A urinary tract infection is a bacterial infection in the bladder or urinary system, and urosepsis is the life-threatening form that occurs when that infection spreads into the bloodstream. People with multiple sclerosis already face higher infection risk because bladder dysfunction, catheter use, disability, and some immune-altering drugs can make infections easier to miss and harder to clear. (aan.com) The database used here is a spontaneous reporting system, which works like a national tip line for side effects rather than a head-to-head trial. It can flag unusual reporting patterns, but it cannot prove that a drug caused an infection or show how often infections occur among all treated patients. (fda.gov) That limitation matters for ocrelizumab because the drug’s label already warns that serious, life-threatening, and fatal infections have occurred, and it tells clinicians to monitor immunoglobulin levels and consider stopping treatment in patients with recurrent serious infections. The current United States prescribing information specifically lists upper and lower respiratory, skin, and herpes infections as recognized risks. (accessdata.fda.gov) Ocrelizumab, sold as Ocrevus by Genentech, is an anti-CD20 antibody that depletes B cells, a type of immune cell involved in multiple sclerosis attacks. The drug won Food and Drug Administration approval in March 2017 for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. (fda.gov) Longer-term company-sponsored safety updates have said the overall serious-infection rate has remained relatively stable in clinical trials and extension studies, with genitourinary infections among the categories tracked in real-world cohorts. Those trial and registry summaries, however, measure treated populations differently from the Food and Drug Administration reporting system and are not directly comparable to disproportionality signals. (medically.gene.com) Neurology Advisor reported the Food and Drug Administration analysis on April 23, 2026, putting a fresh public spotlight on a safety question that drug-safety teams and neurologists will now have to sort through with more formal data. The next step is not a recall or a label change by itself, but a closer look at whether the reporting signal matches real-world infection rates in patients taking the drug. (neurologyadvisor.com)